Defense Department Funds Trial of Potential COVID-19 Treatment

The U.S. Army Medical Research & Development Command has granted Altimmune $4.7 million for a clinical trial of its investigational COVID-19 outpatient treatment.

The Maryland-based drugmaker is planning a phase 1/2 study of T-COVID, an investigational intranasal immune modulator for outpatients with early COVID-19 infections. It expects to begin enrollment within weeks.  

Altimmune plans to begin late-stage trials of T-COVID early next year and expects to file for an Emergency Use Authorization for the treatment.